TG Therapeutics Inc to Discuss UNITY-CLL Phase 3 Trial Conference Call Transcript
Greetings, and welcome to the TG Therapeutics Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Jenna Bosco. Please go ahead, ma'am.
Good morning, and thank you all for joining us today to discuss the positive topline results from the UNITY-CLL Phase III trial. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you to our conference call today.
Following our safe harbor statement, Michael Weiss, the company's Executive Chairman and Chief Executive Officer, will review the topline results from the UNITY trial, and then turn the call over to Dr. Javier Pinilla, the Lymphoma Section Head and Director of Immunotherapy at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and one of our leading enrollers in the UNITY-CLL trial, who will reflect on today's outcome and provide an overview of his
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |